FDA approves new treatment for paediatric patients with type 2 diabetes

FDA

17 June 2019 - The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of paediatric patients 10 years or older with type 2 diabetes. 

Victoza is the first non-insulin drug approved to treat type 2 diabetes in paediatric patients since metformin was approved for paediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.

The efficacy and safety of Victoza for reducing blood sugar in patients with type 2 diabetes was studied in several placebo-controlled trials in adults and one placebo-controlled trial with 134 paediatric patients 10 years and older for more than 26 weeks.

Read FDA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US , Paediatrics